noscript

News and Announcements

Phylogica Engages Financial Advisor to Assess Strategic Opportunities

  • Published April 10, 2013 2:21PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

PERTH, AUSTRALIA: April 10, 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, has engaged Griffin Securities, a specialty investment bank located in New York City, to conduct a formal process for evaluating strategic opportunities available to the Company.

Phylogica’s CEO, Dr Paul Watt, commented: “Over the past few years we have continued to demonstrate the value of our Phylomer platform through the progress of our four alliances with top-10 pharmaceutical companies. We have also further validated the Phylomer approach through our in-house R&D. This has established our technology at the forefront of peptide drug discovery, particularly in the burgeoning new field of intracellular delivery of biological drugs. In addition, Phylomers have potential applications in animal health, agricultural biotech and industrial products.”

To read the full ASX announcement please download the document below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now